Retatrutide showing promise in obesity (and type 2 diabetes)

In a phase 2 clinical trial, retatrutide produced a percentage change in weight from baseline to 24 weeks ranging from -7.2% to -18% as the dose increased from 1 mg to 12 mg.

• Retatrutide stimulates GLP-1, GIP, and glucagon receptors, which are associated with weight loss and glucose regulation.
• The most common side effects reported were gastrointestinal issues, including nausea, diarrhea, and vomiting.
• Heart rate increased by up to 6.7 beats per minute with retatrutide, which may counteract some weight loss benefits.
• The development of retatrutide aims to position it against existing weight loss medications like semaglutide and tirzepatide.
• Currently, there are no ongoing comparator studies between retatrutide and those weight loss drugs.

AI simplified